Bone Regulation of Energy and Male Fertility after SCI

An individual with a SCI in a wheelchair

FOR MORE INFORMATION CLICK HERE

University of Minnesota researchers are seeking participants with or without a spinal cord injury for a clinical trial. We are interested in how bone health affects insulin sensitivity and sperm health in adult males with Spinal Cord Injuries.

Participation in the research will take approximately 5 hours over 3-4 visits. Compensation of $200 will be provided for participation. 
 

University of Minnesota IRB Approved (STUDY00011054)

Tags
Spinal Cord Injury, SCI, Research, Bone, Energy, Fertility

Expand all

Study Personnel

Principal Investigator: Dr. Leslie Morse, DO

Co-Investigator: Ricardo Battaglino, PhD

Data Analyst: Nguyen Nguyen 

Study Coordinator: Tiffany Elliott, MA, OTR/L

Study Coordinator: Brian DeVries

Study Coordinator: Rob Wudlick

 

Inclusion/ Exclusion Criteria

SCI Inclusion Criteria:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male age 18-50
  • Have completed inpatient rehabilitation and are living in the community
  • Have a Spinal Cord Injury 
  • Use a wheelchair as primary mobility mode
  • English and non-English speakers

No SCI Inclusion Criteria:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male age 18-50
  • Able to ambulate independently
  • English and non-English speakers

SCI Exclusion Criteria:

  • presence of other neurological condition
  • use of chronic ventilator support
  • other metabolic bone disease
  • thyroid disorder
  • current use of medications potentially affecting bone health (including bisphosphonates (etidronate or didronel, clodronate or bonefos, tiludronate or skelid, pamidronate, or aredia, alendronate or fosamax, ibandronate or boniva, risedronate or actonel, zoledronate or reclast) parathyroid hormone (forteo, teriparatide, abaloparatide), denosumab (prolia), testosterone, estrogen, anti-epileptics (phenytoin or dilantin, phenobarbital, valproic acid or depakene) lithium, glucocorticoid use for more than 3 months, and those who have received inhaled glucocorticoids in the past year)
  • presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

No SCI Exclusion Criteria:

  • presence of neurological condition
  • other metabolic bone disease
  • thyroid disorder
  • current use of medications potentially affecting bone health (including bisphosphonates (etidronate or didronel, clodronate or bonefos, tiludronate or skelid, pamidronate, or aredia, alendronate or fosamax, ibandronate or boniva, risedronate or actonel, zoledronate or reclast) parathyroid hormone (forteo, teriparatide, abaloparatide), denosumab (prolia), testosterone, estrogen, anti-epileptics (phenytoin or dilantin, phenobarbital, valproic acid or depakene) lithium, glucocorticoid use for more than 3 months, and those who have received inhaled glucocorticoids in the past year)
  • known history of or found on baseline testing to have osteoporosis
  • known history of or found on baseline testing to have diabetes
  • known history of or found on baseline testing to have infertility
  • presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Contact Information

For Study Interest, please click HERE

Email: [email protected]

Phone: 612-301-3072